ProCE Banner Activity

CME

Precision Medicine Advances in Early Breast Cancer: Experts Discuss the Expanding Role of Biomarkers to Guide Neo/Adjuvant Therapy

Video

Watch this on-demand webcast from a live symposium on applying biomarkers to guide treatment in early breast cancer, including discussions on guideline recommendations, planning treatment strategies, adverse event management, and clinical trials.

Physicians: Maximum of 1.50 AMA PRA Category 1 Credits

Released: January 25, 2023

Expiration: January 24, 2024

No longer available for credit.

Share

Faculty

Joyce O’Shaughnessy

Joyce O’Shaughnessy, MD

Co-Director, Breast Cancer Research
Baylor Charles A. Sammons Cancer Center
Texas Oncology
US Oncology
Dallas, Texas

Melinda Telli

Melinda Telli, MD

Professor of Medicine
Stanford University School of Medicine
Director, Breast Cancer Program
Stanford Cancer Institute
Palo Alto, California

Tiffany A. Traina

Tiffany A. Traina, MD

Assistant Attending
Breast Medicine Service
Memorial Sloan Kettering Cancer Center
Assistant Professor
Department of Medicine
Weill Medical College of Cornell University
New York, New York

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by educational grants from AstraZeneca Pharmaceuticals, Lilly, Merck Sharp & Dohme LLC and Sanofi.

AstraZeneca Pharmaceuticals

Lilly

Merck Sharp & Dohme, LLC

Sanofi

Target Audience

This program is intended for physicians and other healthcare professionals who care for patients with breast cancer.

Program Learning Goal

The goal of this activity is to improve the knowledge, confidence, and competence of learners caring for patients with early-stage breast cancer.

Learning Objectives

  • Appraise current/emerging published data and consensus-based guidelines to inform the use of biomarkers and genomic classifiers to assess risk of recurrence, Plan optimal neoadjuvant/adjuvant treatment strategies with approved targeted or immunotherapy agents for appropriate patients with EBC, Develop strategies to anticipate, monitor, and manage adverse events with current and emerging therapies for HR+/HER2- EBC to improve adherence and optimize outcomes, Identify patients with HR+/HER2- EBC eligible for enrollment on ongoing clinical studies investigating novel therapies

  • Plan optimal neoadjuvant/adjuvant treatment strategies with approved targeted or immunotherapy agents for appropriate patients with EBC

  • Develop strategies to anticipate, monitor, and manage adverse events with current and emerging therapies for HR+/HER2- EBC to improve adherence and optimize outcomes
  • Identify patients with HR+/HER2- EBC eligible for enrollment on ongoing clinical studies investigating novel therapies

Disclosure

Clinical Care Options, LLC (CCO) requires instructors, planners, managers, and other individuals who are in a position to control the content of this activity to disclose all financial conflicts of interest (COI) they may have with ineligible companies. All relevant COI are thoroughly vetted and mitigated according to CCO policy. CCO is committed to providing its learners with high-quality CME/CE activities and related materials that promote improvements or quality in healthcare and not a specific proprietary business interest of an ineligible company.

The faculty reported the following relevant financial relationships or relationships to products or devices they have with ineligible companies related to the content of this educational activity:

Primary Author

Joyce O’Shaughnessy, MD

Co-Director, Breast Cancer Research
Baylor Charles A. Sammons Cancer Center
Texas Oncology
US Oncology
Dallas, Texas

Joyce O’Shaughnessy, MD: consultant/advisor/speaker: AbbVie, Agendia, Amgen Biotechnology, Aptitude Health, AstraZeneca, Athenex, Bayer, Bristol-Myers Squibb, Carrick Therapeutics, Celgene, Daiichi Sankyo, Eisai, G1 Therapeutics, Genentech, Genzyme, Gilead Sciences, GRAIL, Halozyme Therapeutics, Heron Therapeutics, Immunomedics, Ipsen Biopharmaceuticals, Lilly, Merck, Myriad, Nektar Therapeutics, Novartis, Ontada, Pfizer, Pharmacyclics, Pierre Fabre, Puma Biotechnology, Roche, Samsung Bioepis, Sandoz, Sanofi, Seagen, Syndax, Synthon, Taiho Oncology, Takeda.

Melinda Telli, MD

Professor of Medicine
Stanford University School of Medicine
Director, Breast Cancer Program
Stanford Cancer Institute
Palo Alto, California

Melinda Telli, MD: consultant/advisor: AstraZeneca, Blueprint Medicines, Daiichi Sankyo, Genentech/Roche, G1 Therapeutics, Gilead Sciences, GlaxoSmithKline, Guardant, Immunomedics, Lilly, Merck, Natera, Novartis, Pfizer, RefleXion, Sanofi; researcher (paid to institution): AbbVie, Bayer, Biothera, Calithera Biosciences, EMD Serono, Genentech, GlaxoSmithKline, Hummingbird Biosciences, Medivation, Novartis, OncoSec, Pfizer, PharmaMar, Tesaro, Vertex.

Tiffany A. Traina, MD

Assistant Attending
Breast Medicine Service
Memorial Sloan Kettering Cancer Center
Assistant Professor
Department of Medicine
Weill Medical College of Cornell University
New York, New York

Tiffany A. Traina, MD: consultant/advisor/speaker: AstraZeneca, Merck; researcher: AstraZeneca.

The planners and content peer reviewers from Clinical Care Options, LLC do not have any relevant financial relationships to disclose.

Format

This program has been made available online.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Accreditation

Joint Accreditation Statement

In support of improving patient care, Clinical Care Options, LLC (CCO) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

Physician Continuing Medical Education

Credit Designation
CCO designates this enduring material for a maximum of 1.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Information

Participation in this self-study activity should be completed in approximately 1.5 hours. To successfully complete this activity and receive credit, participants must follow these steps during the period from January 25, 2023, through January 24, 2024:

1. Register online at http://www.clinicaloptions.com.
2. Read the target audience, learning objectives, and faculty disclosures.
3. Study the educational activity online or printed out.
4. Submit answers to the posttest questions and evaluation questions online.

You must receive a test score of at least 65% and respond to all evaluation questions to receive a certificate. After submitting the evaluation, you may access your online certificate by selecting the certificate link on the posttest confirmation page. Records of all CME/CE activities completed can be found on the "CME/CE Manager" page. There are no costs/fees for this activity.